Breathe BioMedical Inc.

Breathe BioMedical Inc. is a Canadian medical technology company based in Moncton, New Brunswick. Founded in 2005, the company specializes in developing a breath test aimed at enhancing early detection of breast cancer, particularly for women with dense breast tissue. Their core product, the Breast Cancer Breath Test, analyzes exhaled breath to identify biomarkers associated with early-stage breast cancer, achieving an accuracy of 88.2% in distinguishing between affected and unaffected individuals. The company's innovative platform technology integrates four components to collect, process, and analyze breath samples using machine learning models. Currently in the development stage, Breathe BioMedical is conducting proof-of-concept studies and plans to move forward with verification, validation, and large clinical trials to assess safety and efficacy. Their mission is to improve quality of life and save lives through breath-based diagnostics, emphasizing values such as innovation, collaboration, and accountability. Breathe BioMedical is ISO 13485 certified, reflecting its commitment to quality in medical device management.

• Employees 25
• Total Funding $318000